MedImmune, LLC
One MedImmune Way
Gaithersburg
Maryland
20878
United States
Tel: 301-398-0000
Fax: 301-398-9000
Website: http://www.medimmune.com/
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
352 articles about MedImmune, LLC
-
MedImmune, Inc. To Present At The Cowen & Co. 26th Annual Health Care Conference
2/27/2006
-
MedImmune, Inc. Promotes Smullen To Senior Vice President, Sales
2/27/2006
-
MedImmune, Inc. To Present At The Citigroup 2006 Healthcare Conference
2/22/2006
-
MedImmune, Inc. Reports 2005 Financial Results; Posts $22 Million Loss
2/2/2006
-
MedImmune, Inc. To Present At The 2006 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2/1/2006
-
A Diamond In The Rough
2/1/2006
-
MedImmune, Inc. To Announce 2005 Fourth Quarter And Year-End Financial Results On February 2, 2006
1/10/2006
-
MedImmune, Inc. To Present At The 24th Annual JPMorgan Healthcare Conference
1/4/2006
-
FDA Approves MedImmune, Inc.'s State-Of-The-Art Influenza Vaccine Manufacturing Facility
12/27/2005
-
MedImmune, Inc. Completes Enrollment In Phase 3 Study Comparing Numax(TM) To Synagis(R)
12/15/2005
-
MedImmune, Inc. And Biota Holdings Limited Announce Collaboration To Develop New Therapies For RSV Infection; $100M Deal
12/15/2005
-
MedImmune, Inc. Release: Preliminary Data From CAIV-T Pivotal Phase 3 Trial Demonstrate Clinical Efficacy Over Flu Shot In Head-To-Head Influenza Study
12/12/2005
-
MedImmune, Inc. Licensing New Antibody-Enhancing Technologies To Further Strengthen Its Development-Stage Pipeline
12/8/2005
-
MedImmune, Inc. Forms New Cancer Research Partnership
12/8/2005
-
MedImmune, Inc. Expands Oncology Pipeline With Increased Focus On Eph Proteins As Potential Target For New Cancer Therapies
12/8/2005
-
MedImmune, Inc. Licenses Xencor's XmAb(TM) Technology To Create Antibody Therapeutics Against Select Tumor Targets
12/7/2005
-
MedImmune, Inc. Licenses BioWa's POTELLIGENT(TM) Technology For Use In Antibody Development
12/7/2005
-
MedImmune, Inc. Expands Patent Estate For Reverse Genetics With New Rights From Mount Sinai School of Medicine
12/7/2005
-
MedImmune, Inc. Continues To Build Strength And Depth In Management Team
12/6/2005
-
MedImmune, Inc. To Present At The Lazard Capital Markets Life Sciences Conference
11/23/2005